Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633547 | 0.93 | MMP2 (0.42) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL5633562 | 0.93 | MMP3 (0.38) | MMP2MMP9MMP3MMP13BACE1 | |
| SCHEMBL5633872 | 0.86 | RORC (0.39) | MMP2MMP9MMP3MMP13BACE1 | |
| SCHEMBL5634518 | 0.85 | BACE1 (0.42) | MMP2MMP13BACE1KEAP1NFE2L2 | |
| SCHEMBL5633526 | 0.84 | BACE1 (0.43) | MMP2MMP13BACE1KEAP1NFE2L2 | |
| SCHEMBL5172601 | 0.83 | KEAP1 (0.50) | MMP2MMP9MMP3MMP13KEAP1 | |
| SCHEMBL14113252 | 0.81 | — | — | |
| SCHEMBL7248370 | 0.81 | — | — | |
| SCHEMBL4904211 | 0.81 | — | — | |
| SCHEMBL7243370 | 0.79 | BACE1 (0.42) | MMP2MMP13BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | claimed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | MMP2 233/4885MMP9 159/4885MMP3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.